Survival in patients with hepato - Cellular carcinoma treated with 90Y-microsphere radioembolization: Prediction by 18F-FDG PET;Radioembolisation des hepatozellulären karzinoms mit 90Y-mikrosphären: Überlebensprädiktion durch 18F-FDG-PET

NuklearMedizin

Volumn 53, Issue 2, 2014, Pages 39-45

  Sabet, A ^a   Ahmadzadehfar, H ^a   Bruhman, J ^a   Meyer, C ^a   Wasmuth, J C ^a   Pieper, C C ^a   Biersack, H J ^a   Ezziddin, Samer ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

HCC; Radioembolization; SIRT

Indexed keywords

AMINOTRANSFERASE; FLUORODEOXYGLUCOSE F 18; MICROSPHERE; YTTRIUM 90; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HISTOLOGY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVER CELL CARCINOMA; MALE; MIDDLE AGED; NAUSEA; OVERALL SURVIVAL; PULMONARY SHUNT; RADIATION DOSE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VERY ELDERLY; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC USE; LIVER NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; YTTRIUM RADIOISOTOPES;

EID: 84899700105     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/Nukmed-0622-13-09     Document Type: Article

References (38)

1. 123I-MIBG whole body scan scoring method-application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995; 31A: 256-261.
2. Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med 2010; 40: 105-121.
3. 90Y resin microspheres. A safe calculation method. Nuklearmedizin 2013; 53.
4. 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging 2005; 32: 778-787.
5. 18F-fluorode-oxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010; 16: 978-985.
6. Bruix J et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
8. 18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy? Radiother Oncol 2012; 103: 63-68.
9. 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun 2005; 26: 689-694.
10. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
11. 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 2009; 50: 858-864.
12. Geschwind JF, Salem R, Carr BI et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127: S194-205.
13. 90Y microspheres. Eur J Nucl Med Mol Imaging 2011; 38: 1037-1045.
14. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med 2012; 53: 371-377.
15. Higashi T et al. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2010; 37: 468-482.
16. Ibrahim SM, Lewandowski RJ, Sato KT et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 2008; 14: 1664-1669.
17. Jiao LR, Szyszko T, Al-Nahhas A et al. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. Eur J Surg Oncol 2007; 33: 597-602.
18. Juweid ME, Cheson BD. Positron emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354: 496-507.
19. Kennedy A, Nag S, Salem R et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radio-embolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68: 13-23.
20. Khan MA et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32: 792-797.
21. Khodjibekova M, Szyszko T, Khan S et al. Selective internal radiation therapy with yttrium-90 for unresectable liver tumours. Rev Recent Clin Trials 2007; 2: 212-216.
22. 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT. Clin Nucl Med 2013; 38: e283-289.
23. Lencioni R, Llovet JM. Modified RECIST assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
24. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
25. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200.
26. 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16: 1627-1639.
27. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006; 17: 1251-1278.
28. Salem R, Lewandowski RJ, Mulcahy MF et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64.
29. Sangro B, Bilbao JI, Boan J et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 792-800.
30. Shiomi S, Nishiguchi S, Ishizu H et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001; 96: 1877-1880.
31. 18F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies. World J Gastroenterol 2011; 17: 5059-5074.
32. Song P et al. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int 2012; 32: 1053-1063.
33. 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun 2007; 28: 15-20.
34. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
35. 18F]-Fluorodeoxyglucosepositron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2009; 250: 888-894.
36. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006; 24: 3282-3292.
37. 18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 2002; 29: 815-820.
38. 90Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging 2012; 39: 1391-1399.